Network and systems biology: essential steps in virtualising drug discovery and development.

The biological processes that keep us healthy or cause disease, as well as the mechanisms of action of possible drugs are inherently complex. In the face of this complexity, attempts at discovering new drugs to treat diseases have alternated between trial-and-error (typically on experimental systems) and grand simplification, usually based on much too little information. We now have the chance to combine these strategies through establishment of 'virtual patient' models, centred on a detailed molecular characterisation of thousands or even, in the future, millions of patients. In doing so, we lay the foundations for truly personalised therapy, as well as a far-reaching virtualisation of drug discovery and development in oncology and other areas of medicine.

[1]  A. Nobel,et al.  Concordance among Gene-Expression – Based Predictors for Breast Cancer , 2011 .

[2]  M Heath-Chiozzi,et al.  Clinical application of pharmacogenetics. , 2001, Trends in molecular medicine.

[3]  O Mason,et al.  Graph theory and networks in Biology. , 2006, IET systems biology.

[4]  R. Iyengar Complex diseases require complex therapies , 2013, EMBO reports.

[5]  Ralf Herwig,et al.  ConsensusPathDB: toward a more complete picture of cell biology , 2010, Nucleic Acids Res..

[6]  M. Dunning,et al.  Genome-driven integrated classification of breast cancer validated in over 7,500 samples , 2014, Genome Biology.

[7]  Ralf Herwig,et al.  ConsensusPathDB—a database for integrating human functional interaction networks , 2008, Nucleic Acids Res..

[8]  David M. Wilson,et al.  Network biology as a new approach to drug discovery. , 2010, Current opinion in drug discovery & development.

[9]  Mark A. Murcko,et al.  Virtual screening : an overview , 1998 .

[10]  Ulrich Keilholz,et al.  Personalized medicine approaches for colon cancer driven by genomics and systems biology: OncoTrack , 2014, Biotechnology journal.

[11]  Albert-László Barabási,et al.  Observability of complex systems , 2013, Proceedings of the National Academy of Sciences.

[12]  T. Ideker,et al.  Network-based classification of breast cancer metastasis , 2007, Molecular systems biology.

[13]  F. Bertucci,et al.  EndoPredict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer. , 2014, Cancer letters.

[14]  C. Cobelli,et al.  In Silico Preclinical Trials: A Proof of Concept in Closed-Loop Control of Type 1 Diabetes , 2009, Journal of diabetes science and technology.

[15]  Bertram Klinger,et al.  Supplementary Materials for : Network quantification of EGFR signaling unveils potential for targeted combination therapy , 2022 .

[16]  H. Lehrach DNA sequencing methods in human genetics and disease research , 2013, F1000prime reports.

[17]  L. Hutchinson,et al.  High drug attrition rates—where are we going wrong? , 2011, Nature Reviews Clinical Oncology.

[18]  Jens Timmer,et al.  Systems-level interactions between insulin–EGF networks amplify mitogenic signaling , 2009, Molecular systems biology.

[19]  H. Lehrach,et al.  IT Future of Medicine: from molecular analysis to clinical diagnosis and improved treatment. , 2013, New biotechnology.

[20]  David R. Gilbert,et al.  Computational modelling of cancerous mutations in the EGFR/ERK signalling pathway , 2009, BMC Systems Biology.

[21]  Jeffrey R. Whiteaker,et al.  Proteogenomic characterization of human colon and rectal cancer , 2014, Nature.

[22]  H. Lehrach,et al.  Resources, standards and tools for systems biology. , 2007, Briefings in functional genomics & proteomics.

[23]  Nathan D. Price,et al.  Demystifying Disease, Democratizing Health Care , 2014, Science Translational Medicine.

[24]  Hans Lehrach,et al.  Future of medicine: models in predictive diagnostics and personalized medicine. , 2013, Advances in biochemical engineering/biotechnology.

[25]  Andriani Daskalaki,et al.  High-Throughput miRNA and mRNA Sequencing of Paired Colorectal Normal, Tumor and Metastasis Tissues and Bioinformatic Modeling of miRNA-1 Therapeutic Applications , 2013, PloS one.

[26]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[27]  Jeffrey T. Chang,et al.  Oncogenic pathway signatures in human cancers as a guide to targeted therapies , 2006, Nature.

[28]  N. Kikuchi,et al.  CellDesigner 3.5: A Versatile Modeling Tool for Biochemical Networks , 2008, Proceedings of the IEEE.

[29]  J. Foekens,et al.  Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.

[30]  Anne Mai Wassermann,et al.  Bioturbo Similarity Searching: Combining Chemical and Biological Similarity To Discover Structurally Diverse Bioactive Molecules , 2013, J. Chem. Inf. Model..

[31]  A. Y. Lu,et al.  Pharmacogenetics, Pharmacogenomics, and Individualized Medicine , 2011, Pharmacological Reviews.

[32]  R. Shoemaker The NCI60 human tumour cell line anticancer drug screen , 2006, Nature Reviews Cancer.

[33]  Hugo Y. K. Lam,et al.  Personal Omics Profiling Reveals Dynamic Molecular and Medical Phenotypes , 2012, Cell.

[34]  A. Barabasi,et al.  Systems biology and the future of medicine , 2011, Wiley interdisciplinary reviews. Systems biology and medicine.

[35]  Xiang-Dong Fu,et al.  Versatile pathway-centric approach based on high-throughput sequencing to anticancer drug discovery , 2012, Proceedings of the National Academy of Sciences.

[36]  M. Ramanathan,et al.  Network‐Based Approaches in Drug Discovery and Early Development , 2013, Clinical pharmacology and therapeutics.

[37]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[38]  Brad T. Sherman,et al.  Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists , 2008, Nucleic acids research.

[39]  Barbara M. Bakker,et al.  Emergence of the silicon human and network targeting drugs. , 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[40]  Andriani Daskalaki,et al.  Prediction in the face of uncertainty: a Monte Carlo-based approach for systems biology of cancer treatment. , 2012, Mutation research.

[41]  Reinhard Schneider,et al.  Using graph theory to analyze biological networks , 2011, BioData Mining.

[42]  Eytan Domany,et al.  Outcome signature genes in breast cancer: is there a unique set? , 2004, Breast Cancer Research.

[43]  Jérôme Hert,et al.  New Methods for Ligand-Based Virtual Screening: Use of Data Fusion and Machine Learning to Enhance the Effectiveness of Similarity Searching , 2006, J. Chem. Inf. Model..

[44]  J. V. Moran,et al.  Initial sequencing and analysis of the human genome. , 2001, Nature.

[45]  W. Gradishar,et al.  Clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: a systematic review. , 2012, Journal of the National Cancer Institute.

[46]  T. Fan,et al.  The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. , 2012, Cell metabolism.

[47]  Dipak Barua,et al.  Modeling the Effect of APC Truncation on Destruction Complex Function in Colorectal Cancer Cells , 2013, PLoS Comput. Biol..

[48]  Gary D Bader,et al.  Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2+:ERα− breast cancer , 2012, Proceedings of the National Academy of Sciences.

[49]  Zachary A. King,et al.  Constraint-based models predict metabolic and associated cellular functions , 2014, Nature Reviews Genetics.

[50]  Sabine Tejpar,et al.  Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer , 2013, The Journal of pathology.

[51]  Rudi Balling,et al.  Revolutionizing medicine in the 21st century through systems approaches. , 2012, Biotechnology journal.

[52]  Daniel C Kirouac,et al.  Computational Modeling of ERBB2-Amplified Breast Cancer Identifies Combined ErbB2/3 Blockade as Superior to the Combination of MEK and AKT Inhibitors , 2013, Science Signaling.

[53]  Ruth Nussinov,et al.  Structure and dynamics of molecular networks: A novel paradigm of drug discovery. A comprehensive review , 2012, Pharmacology & therapeutics.

[54]  Michael R. Green,et al.  Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma. , 2012, Cancer cell.

[55]  Jean YH Yang,et al.  Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.

[56]  C. Sander,et al.  Integrative Subtype Discovery in Glioblastoma Using iCluster , 2012, PloS one.

[57]  Mudita Singhal,et al.  COPASI - a COmplex PAthway SImulator , 2006, Bioinform..

[58]  Ronan M. T. Fleming,et al.  A community-driven global reconstruction of human metabolism , 2013, Nature Biotechnology.

[59]  Costas Kravaris,et al.  Advances and selected recent developments in state and parameter estimation , 2013, Comput. Chem. Eng..

[60]  Corbin E. Meacham,et al.  Tumour heterogeneity and cancer cell plasticity , 2013, Nature.

[61]  S. Huang,et al.  Genomics, complexity and drug discovery: insights from Boolean network models of cellular regulation. , 2001, Pharmacogenomics.

[62]  Gary D. Bader,et al.  Pathway Commons, a web resource for biological pathway data , 2010, Nucleic Acids Res..

[63]  B. Al-Lazikani,et al.  Combinatorial drug therapy for cancer in the post-genomic era , 2012, Nature Biotechnology.

[64]  M. Abba,et al.  Breast Cancer Biomarker Discovery in the Functional Genomic Age: A Systematic Review of 42 Gene Expression Signatures , 2010, Biomarker insights.

[65]  A. Sarai,et al.  Genetic algorithm optimization in drug design QSAR: Bayesian-regularized genetic neural networks (BRGNN) and genetic algorithm-optimized support vectors machines (GA-SVM) , 2011, Molecular Diversity.

[66]  H. Lehrach,et al.  The “Virtual Patient” system: modeling cancer using deep sequencing technologies for personalized cancer treatment , 2012, Journal für Verbraucherschutz und Lebensmittelsicherheit.

[67]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[68]  Gary D Bader,et al.  International network of cancer genome projects , 2010, Nature.

[69]  S. Friend,et al.  A network view of disease and compound screening , 2009, Nature Reviews Drug Discovery.